Abstract：Tuberculosis is a serious zoonotic disease caused by Mycobacterium tuberculosis. With the evolution of M. tuberculosis and the use of anti-tuberculosis drugs, Mycobacterium tuberculosis has developed drug resistance. Depending on whether patients with TB have received anti-tuberculosis drug treatment, the drug resistance of Mycobacterium tuberculosis is mainly divided into two types, one is primary drug resistance and the other is acquired drug resistance. In order to explore the drug resistance mechanism of Mycobacterium tuberculosis, this article describes mechanisms of the primary and acquired drug resistance mechanisms in order to lay a theoretical foundation for the subsequent research and development of new anti-tuberculosis drugs.
郑伟, 田甜, 王琦, 刁乃超, 李健明, 时坤, 杜锐. 结核分枝杆菌的耐药机制研究进展[J]. 中国人兽共患病学报, 2021, 37(11): 1044-1052.
ZHENG Wei, TIAN Tian, WANG Qi, DIAO Nai-chao, LI Jian-ming, SHI Kun, DU Rui. Research progress on the drug resistance mechanism of Mycobacterium tuberculosis. Chinese Journal of Zoonoses, 2021, 37(11): 1044-1052.
[1] Herfst S, Böhringer M, Karo B, et al.Drivers of airborne human-to-human pathogen transmission[J]. Curr Opin Virol, 2017, 22: 22-29. DOI: 10.1016/j.coviro.2016.11.006 [2] Chin JH.Neurotuberculosis: a clinical review[J]. Semin Neurol, 2019, 39(4): 456-461. DOI: 10.1055/s-0039-1687840 [3] Agudelo CA, álvarez MF, Hidrón A, et al.Outcomes and complications of hospitalised patients with HIV-TB co-infection[J]. Trop Med Int Health, 2021, 26(1): 82-88. DOI: 10.1111/tmi.13509 [4] 宋禹昊, 李东, 孙江洋,等. CRISPR/Cas系统及其在结核分枝杆菌研究中的应用[J]. 畜牧兽医学报, 2020, 51(11): 2613-2621.DOI:10.11843/j.issn.0366-6964.2020.11.001 [5] Bhat ZS, Rather MA, Maqbool M, et al.Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis[J]. Biomed Pharmacother,2017,95:1520-1534. DOI: 10.1016/j.biopha.2017.09.036 [6] Stucki D, Gagneux S .Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database[J]. Tuberculosis,2013,93(1):30-39. DOI: 10.1016/j.tube.2012.11.002 [7] Caminero Luna JA, Pérez Mendoza G, Rodríguez de Castro F. Multi-drug resistant tuberculosis, ten years later[J]. Med Clin (Barc), 2021, 156(8): 393-401. DOI: 10.1016/j.medcli.2020.08.018 [8] Allué-Guardia A, García JI, Torrelles JB.Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment[J]. Front Microbiol, 2021,12:137. DOI: 10.3389/fmicb.2021.612675 [9] da Silva PE, Von Groll A, Martin A, et al. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis[J]. FEMS Immunol Med Microbiol,2011,63(1):1-9. DOI: 10.1111/j.1574-695X.2011.00831.x [10] Batt SM, Burke CE, Moorey AR, et al.Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall[J]. Cell Surf, 2020, 6: 100044. DOI: 10.1016/j.tcsw.2020.100044 [11] Brennan PJ.Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis[J]. Tuberculosis (Edinb), 2003, 83(1/3): 91-97. DOI: 10.1016/s1472-9792(02)00089-6 [12] Alderwick LJ, Harrison J, Lloyd GS, et al.The mycobacterial cell wall—peptidoglycan and arabinogalactan[J]. Cold Spring Harb Perspect Med, 2015, 5(8): a021113. DOI: 10.1101/cshperspect.a021113 [13] Birch HL, Alderwick LJ, Bhatt A, et al.Biosynthesis of mycobacterial arabinogalactan: identification of a novel alpha(1->3) arabinofuranosyltransferase[J]. Mol Microbiol, 2008, 69(5): 1191-1206. DOI: 10.1111/j.1365-2958.2008.06354.x [14] Shi T, Fu T, Xie J.Polyphosphate deficiency affects the sliding motility and biofilm formation of Mycobacterium smegmatis[J]. Curr Microbiol, 2011, 63(5): 470-476. DOI: 10.1007/s00284-011-0004-4 [15] Goude R, Parish T.The genetics of cell wall biosynthesis in Mycobacterium tuberculosis[J]. Future Microbiol, 2008, 3(3): 299-313. DOI: 10.2217/17460913.3.3.299 [16] Bhatt A, Fujiwara N, Bhatt K, et al.Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice[J]. Proc Natl Acad Sci U S A, 2007, 104(12): 5157-5162. DOI: 10.1073/pnas.0608654104 [17] Singh R, Dwivedi SP, Gaharwar US, et al.Recent updates on drug resistance in Mycobacterium tuberculosis[J]. J Appl Microbiol, 2020, 128(6): 1547-1567. DOI: 10.1111/jam.14478 [18] Khawbung JL, Nath D, Chakraborty S.Drug resistant Tuberculosis: a review[J]. Comp Immunol Microbiol Infect Dis, 2021, 74:101574. DOI.10.1016/j.cimid.2020.101574 [19] Hameed HMA, Islam MM, Chhotaray C, et al.Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains[J]. Front Cell Infect Microbiol, 2018, 8: 114. DOI: 10.3389/fcimb.2018.00114 [20] Farhat MR, Sultana R, Iartchouk O, et al.Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value[J]. Am J Respir Crit Care Med, 2016, 194(5): 621-630. DOI: 10.1164/rccm.201510-2091OC [21] Miotto P, Zhang Y, Cirillo DM, et al.Drug resistance mechanisms and drug susceptibility testing for tuberculosis[J]. Respirology, 2018, 23(12): 1098-1113. DOI: 10.1111/resp.13393 [22] Islam MM, Hameed HMA, Mugweru J, et al.Drug resistance mechanisms and novel drug targets for tuberculosis therapy[J]. J Genet Genomics, 2017, 44(1): 21-37. DOI: 10.1016/j.jgg.2016.10.002 [23] Sinha P, Srivastava GN, Tripathi R, et al.Detection of mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains inhibiting wild type probe hybridization in the MTBDR plus assay by DNA sequencing directly from clinical specimens[J]. BMC Microbiol, 2020,20(1):284. DOI: 10.1186/s12866-020-01967-5 [24] Arun KB, Madhavan A, Abraham B, et al.Acetylation of isoniazid is a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2020, 65(1): e00456-20. DOI: 10.1128/AAC.00456-20 [25] Hsu LY, Lai LY, Hsieh PF, et al.Two novel katG mutations conferring isoniazid resistance in Mycobacterium tuberculosis[J]. Front Microbiol, 2020, 11: 1644. DOI: 10.3389/fmicb.2020.01644 [26] Cook GW, Benton MG, Akerley W, et al.Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencing[J]. PLoS One, 2020,15(1):e0226340. DOI: 10.1371/journal.pone.0226340 [27] Arun KB, Madhavan A, Abraham B, et al.Acetylation of isoniazid is a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother,2020,65(1):e00456-20. DOI: 10.1128/AAC.00456-20 [28] Xiang X, Gong Z, Deng W, et al.Mycobacterial ethambutol responsive genes and implications in antibiotics resistance[J]. J Drug Target, 2021, 29(3): 284-293. DOI: 10.1080/1061186X.2020.1853733 [29] Lingaraju S, Rigouts L, Gupta A, et al.Geographic differences in the contribution of ubiA mutations to High-Level ethambutol resistance in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2016, 60(7): 4101-4105. DOI: 10.1128/AAC.03002-15 [30] Sharma K, Gupta M, Krupa A, et al.EmbR, a regulatory protein with ATPase activity, is a substrate of multiple serine/threonine kinases and phosphatase in Mycobacterium tuberculosis[J]. FEBS J, 2006,273(12):2711-2721. DOI: 10.1111/j.1742-4658.2006.05289.x [31] den Hertog AL, Sengstake S, Anthony RM. Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite?[J]. Pathog Dis, 2015, 73(6): ftv037. DOI: 10.1093/femspd/ftv037 [32] Zhang N, Savic RM, Boeree MJ, et al.Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Networks. Optimising pyrazinamide for the treatment of tuberculosis[J]. Eur Respir J, 2021, 4:2002013. DOI: 10.1183/13993003.02013-2020 [33] Wang Y, Li Q, Gao H, et al.The roles of rpsL, rrs, and gidB mutations in predicting streptomycin-resistant drugs used on clinical Mycobacterium tuberculosis isolates from Hebei Province, China[J]. Int J Clin Exp Pathol, 2019, 12(7): 2713-2721. [34] Krüüner A, Jureen P, Levina K, et al.Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2003, 47(9): 2971-2973. DOI: 10.1128/AAC.47.9.2971-2973.2003 [35] Islam MM, Tan Y, Hameed HMA, et al.Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China[J]. J Glob Antimicrob Resist, 2020, 22: 290-295. DOI: 10.1016/j.jgar.2020.02.019 [36] Maus CE, Plikaytis BB, Shinnick TM.Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2005, 49(8): 3192-3197. DOI: 10.1128/AAC.49.8.3192-3197.2005 [37] Prieri M, Frita R, Probst N, et al.Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis[J]. Eur J Med Chem, 2018, 159: 35-46. DOI: 10.1016/j.ejmech.2018.09.038 [38] Mugumbate G, Mendes V, Blaszczyk M, et al.Target identification of Mycobacterium tuberculosis phenotypic hits using a concerted chemogenomic, biophysical, and structural approach[J]. Front Pharmacol, 2017, 8: 681. DOI: 10.3389/fphar.2017.00681 [39] Song Y, Wang G, Li Q, et al.The value of the inhA mutation detection in predicting ethionamide resistance using melting curve technology[J]. Infect Drug Resist, 2021,14:329-334. DOI: 10.2147/IDR.S268799 [40] Von Groll A, Martin A, Jureen P, et al.Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB[J]. Antimicrob Agents Chemother, 2009, 53(10): 4498-4500. DOI: 10.1128/AAC.00287-09 [41] Chawla K, Kumar A, Shenoy VP, et al.Genotypic detection of fluoroquinolone resistance in drug-resistant Mycobacterium tuberculosis at a tertiary care centre in south Coastal Karnataka, India[J]. J Glob Antimicrob Resist, 2018, 13:250-253. DOI: 10.1016/j.jgar.2018.01.023 [42] Wang X, Yang S, Gu J, et al.Mycobacterium tuberculosis Arylamine N-Acetyltransferase acetylates and thus inactivates para-aminosalicylic acid[J]. Antimicrob Agents Chemother, 2016, 60(12): 7505-7508. DOI: 10.1128/AAC.01312-16 [43] Wei W, Yan H, Zhao J, et al.Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains[J]. Emerg Microbes Infect, 2019, 8(1): 248-261. DOI: 10.1080/22221751.2019.1568179 [44] Prosser GA, Rodenburg A, Khoury H, et al.Glutamate racemase is the primary target of β-Chloro-d-Alanine in Mycobacterium tuberculosis[J].Antimicrob Agents Chemother, 2016,60(10):6091-6099. DOI: 10.1128/AAC.01249-16 [45] Evangelopoulos D, Prosser GA, Rodgers A, et al.Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes[J]. Nat Commun, 2019, 10(1): 4177. DOI: 10.1038/s41467-019-12074-z [46] Wasserman S, Meintjes G, Maartens G.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index[J].Expert Rev Anti Infect Ther,2016,14(10):901-915. DOI: 10.1080/14787210.2016.1225498 [47] Bolhuis MS, van der Laan T, Kosterink JG, et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis[J]. Eur Respir J, 2014, 44(3): 808-811. DOI: 10.1183/09031936.00041314 [48] Fermeli DD, Marantos TD, Liarakos AD, et al.Linezolid: a promising agent for the treatment of multiple and extensively Drug-Resistant Tuberculosis[J].Folia Med (Plovdiv),2020,62(3):444-452. DOI: 10.3897/folmed.62.e48742 [49] Gopal M, Padayatchi N, Metcalfe JZ, et al.Systematic review of clofazimine for the treatment of drug-resistant tuberculosis[J]. Int J Tuberc Lung Dis, 2013, 17(8): 1001-1007. DOI: 10.5588/ijtld.12.0144 [50] Mothiba MT, Anderson R, Fourie B, et al.Effects of clofazimine on planktonic and biofilm growth of Mycobacterium tuberculosis and Mycobacterium smegmatis[J].J Glob Antimicrob Resist,2015,3(1):13-18. DOI: 10.1016/j.jgar.2014.12.001 [51] Fatima S, Bhaskar A, Dwivedi VP.Repurposing immunomodulatory drugs to combat tuberculosis[J].Front Immunol,2021,12:645485. DOI: 10.3389/fimmu.2021.645485 [52] Li Y, Sun F, Zhang W.Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging[J]. Drug Dev Res, 2019,80(1):98-105. DOI: 10.1002/ddr.21498 [53] Ismail N, Peters RPH, Ismail NA, et al.Clofazimine Exposure in vitro selects efflux pump mutants and bedaquiline resistance[J]. Antimicrob Agents Chemother, 2019, 63(3): e02141-18. DOI: 10.1128/AAC.02141-18 [54] Ismail N, Ismail NA, Omar SV, et al.In Vitro study of stepwise Acquisition of rv0678 and atpE mutations conferring bedaquiline resistance[J]. Antimicrob Agents Chemother, 2019, 63(8): 248-261. DOI: 10.1128/AAC.00292-19 [55] Van den Bossche A, Varet H, Sury A, et al. Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid[J]. Tuberculosis (Edinb), 2019, 117:18-23. DOI: 10.1016/j.tube.2019.05.002 [56] Mallikaarjun S, Wells C, Petersen C, et al.Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects[J].Antimicrob Agents Chemother,2016,60(10):5976-5985. DOI: 10.1128/AAC.00509-16 [57] Liu Y, Matsumoto M, Ishida H, et al.Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)[J].Tuberculosis (Edinb), 2018,111:20-30. DOI: 10.1016/j.tube.2018.04.008 [58] Thakare R, Dasgupta A, Chopra S.Pretomanid for the treatment of pulmonary tuberculosis[J]. Drugs Today (Barc), 2020,56(10):655-668. DOI: 10.1358/dot.2020.56.10.3161237 [59] Sacksteder KA, Protopopova M, Barry CE 3rd, et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action[J]. Future Microbiol,2012,7(7):823-837. DOI: 10.2217/fmb.12.56 [60] Zhang B, Li J, Yang X, et al.Crystal structures of membrane transporter MmpL3, an anti-TB drug target[J]. Cell, 2019, 176(3): 636-648. DOI: 10.1016/j.cell.2019.01.003 [61] Jia L, Tomaszewski JE, Hanrahan C, et al.Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug[J].Br J Pharmacol, 2005,144(1):80-87. DOI: 10.1038/sj.bjp.0705984
2021, Vol. 37 
